Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

Study Title

Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

Teva Identifier

C38072/3084

ClinicalTrials.gov Identifier

NCT01508936

Study Status

Completed

Trial Condition(s)

Eosinophilic Asthma

Interventions

Drug: Reslizumab | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Click for participation criteria and map of study locations

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 65 Years

Trial Duration

02/01/2012 - 08/01/2013

Phase

Phase 3

Study Type

Interventional